Lyra Therapeutics (LYRA) Earnings Call Presentation

ENLIGHTEN 2 Study Results ENLIGHTEN 2: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in Adults https://clinicaltrials.gov/study/NCT05295459 June 2, 2025 FLS Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," an ...